Clinical Trial Update: Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of an MVA85A prime vaccination followed by BCG boost for tuberculosis in individuals with TB and/or HIV has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)
• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: Mark Hatherill | Conditions: Tuberculosis, HIV | Phase 2 | Status: COMPLETED